

Editor Biography



Dr Ved Srivastava is Vice President of Chemistry at Intarcia Therapeutics and President of the American Peptide Society. Prior to that, he was the Head of Peptide Chemistry at GlaxoSmithKline (USA) and in the senior leadership role at Amylin Pharmaceuticals (now AstraZeneca US). He co-founded Phoundry Pharmaceuticals, a biotech company focused on the discovery of peptide hormone therapeutics. Phoundry was acquired by Intarcia Therapeutics in 2015.

Ved spent several years in a leadership role with Amylin Pharmaceuticals where he focused on the discovery and development of novel peptide hormones for diabetes, obesity and neuropsychiatric therapies. He has participated in the development and commercialization of SYMLIN[®], Byetta[®] and BYDUREON[®] first-in-class medicines for the treatment of diabetes.

Ved has over 25 years of experience with expertise in drug discovery and development in the area of metabolic diseases, CNS and inflammation with major emphasis in peptide medicinal chemistry, chemistry manufacturing and control (CMC) and peptide drug delivery. He has numerous scientific disclosures including patents, scientific articles and invited lectures.

Ved is the Editor of three other books: (1) *Peptide-based Drug Discovery: Challenges and New Therapeutics* (Royal Society of Chemistry), (2) *Comprehensive Medicinal Chemistry III*, Volume 6, Biologics Medicine (Elsevier) and (3) *Peptide 2015* (American Peptide Society). He is an Editorial Board member of *The FASEB Journal* of the Federation of American Societies for

Drug Discovery Series No. 72

Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing and Controls
Edited by Ved Srivastava

© The Royal Society of Chemistry 2019

Published by the Royal Society of Chemistry, www.rsc.org

Experimental Biology and the Editor-in-chief of the *Drug Development Series* books of the Royal Society of Chemistry.

Ved serves in the governance and leadership team of the American Peptide Society (APS) and the American Chemical Society (ACS) and other peptide societies. Ved is also an appointed member of the BIO1 – Peptides and Insulins Expert Committee and the Therapeutic Peptides Expert Panel of the US Pharmacopeia (USP) in partnership with the FDA. He earned a PhD in organic chemistry from the University of Lucknow, India, and had subsequent postdoctoral appointments at the University of Georgia and the University of Colorado Medical School.

